Despite advances in current treatment options, Hepatocellular Carcinoma (HCC) recurrence still presents as a significant clinical challenge. After initial treatment, HCC occurs considerable portion of patients without an available standardized protocol for managing such incident. Recurrence advanced liver disease may make surgical options impossible, which case, locoregional therapy should be c...

AMA Wang Y, Zhang W, Bao L, Lu Hong J. Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma. Videosurgery and Other Miniinvasive Techniques/Wideochirurgia i inne techniki małoinwazyjne. 2023. doi:10.5114/wiitm.2023.131539. APA Wang, Y., Zhang, W., Bao, L., Lu, & Hong, (2023). https://doi.org/10.5114/wiitm.2023.131539 Chicago You-Bin, Wei Le Yun Jiao H...

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...

PURPOSE To compare retrospectively the outcomes and complications of transcatheter arterial chemoembolization with drug-eluting embolic agents combined with radiofrequency (RF) ablation or microwave (MW) ablation in treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS From 2003-2011, 89 patients with HCC received a combination therapy-transcatheter arterial chemoembolization plu...

Hepatocellular carcinoma (HCC) is one of the most common cancers and the third highest cause of cancer-associated mortality worldwide. The treatment of HCC is complicated by its variable biological behavior and the frequent coexistence of chronic liver disease, particularly cirrhosis. To date, multiple treatment modalities have been developed according to the stage of the tumor and the hepatic ...

Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related mortality. Despite the widespread implementation of surveillance programs, more than half of the patients with HCC are diagnosed at late stages, when curative treatments (resection or liver transplantation) cannot be applied. For patients presenting with unre...

This randomized, controlled trial assessed the efficacy of transarterial Lipiodol (Lipiodol Ultrafluide, Laboratoire Guerbet, Aulnay-Sous-Bois, France) chemoembolization in patients with unresectable hepatocellular carcinoma. From March 1996 to October 1997, 80 out of 279 Asian patients with newly diagnosed unresectable hepatocellular carcinoma fulfilled the entry criteria and randomly were ass...

BACKGROUND There is no consensus regarding the selection of treatment options for hepatocellular carcinoma (HCC) after initial transarterial chemoembolization (TACE). This meta-analysis aimed to explore the survival benefit of hepatic resection after initial TACE for the treatment of HCC. MATERIALS AND METHODS We searched three major databases to identify all relevant papers comparing the out...

Transarterial chemoembolization (TACE) using doxorubicin-eluting beads (DEBs) have been introduced as a novel device which ensures more sustained and tumor-selective drug delivery and permanent embolization compared to conventional TACE with lipiodol. Studies highlighting the use of TACE with DEBs for the treatment of hepatocellular carcinoma (HCC) have shown similar or better results compared ...